60,000 sq ft flagship office and laboratory building now fully let
Cambridge, 9th January 2023: Leading regional property investor and developer Howard Group is delighted to welcome Chimeris UK Limited to Unity Campus. The biotech company has secured Suite 5 (8,000 sq ft), the last available space within ‘The Works’ building, thereby completing the leasing of phase 1 at Unity Campus.
As part of the letting, Howard Group is fitting out Suite 5 as CL2 wet laboratory space. McManniman has been appointed to deliver the…
Cambridge, UK, 05 January 2023: PhoreMost Ltd., has triggered a milestone payment in its multi-project target discovery collaboration with Boehringer Ingelheim. This was achieved by identifying and validating novel targets supporting Boehringer Ingelheim’s ambition to develop first-in-class therapies, to transform patients’ lives.
PhoreMost and Boehringer Ingelheim entered a multi-project collaboration back in January 20201, with PhoreMost deploying its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, towards disease-relevant pathways selected by Boehringer…
Marks & Clerk are proud to present The IP Driven Start-up e-book, which is released today!
Authored by Robert Lind, leading intellectual property firm Marks & Clerk brings you a pithy summary of the issues facing the IP driven start up and how to deal with these.
This book emphasises what the founders need to put in place at the outset to secure their IP assets and ensure that maximum value is obtained at the point of exit. It also considers the steps that need to be taken to manage growth and avoid IP assets slipping through the net.
To request your free download of the book, please…
We’re helping NeoVac fast-track its revolutionary lipid nanoparticle technology to clinical trials, to make RNA vaccines and therapies more transportable and able to tackle multiple pathogen variants while having fewer side effects compared with existing licensed vaccines.
Through this partnership, we will enable and accelerate the clinical testing of NeoVac’s lipid nanoparticle (LNP) drug delivery technology. We will develop scalable processes and manufacture clinical-grade batches of RNA-LNP product, focusing initially on doses to tackle new and emergent variants of COVID-19, before…
Cambridge, UK, 3rd January 2023, Astex Pharmaceuticals, UK, congratulates Harren Jhoti, PhD, FRS, FMedSci, its co-founder, President and CEO on being honoured in the 2023 King’s New Year Honours list. Dr Jhoti has been made an Officer of the Order of the British Empire (OBE) for services to Cancer Research and Drug Discovery.
Dr. Jhoti co-founded Astex in 1999 to pioneer the development of fragment-based drug discovery (FBDD), a ground-breaking new approach now widely used in the pharmaceutical industry, and which the company has used to help discover two new marketed cancer…
Key strategic appointment as the Company enters next phase of commercial growth and global expansion of its products and services
Former CEO, Dr David Hughes, appointed to Scientific Advisory Board
Cambridge, UK, 19 December 2022: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the appointment of Dr Paul Brooks, formerly the Company’s Chief Business Officer, to the position of CEO with immediate effect. Former CEO, Dr David Hughes, will continue to work with the company in a consultative…
Click here to view the December 2022 edition of The Meeting Place
Asahi Kasei Pharma offers collaborative research opportunities with research funding and our scientists’ contribution through research activities.
We will be accepting research proposals for 2023 during the following period.5:00AM, Jan 5, 2023 GMT to 8:00AM, Feb 28, 2023 GMT
A short video overviewing the program is now available!
More information here
”ASAHI KASEI PHARMA OPEN INNOVATION” is an open innovation platform started in 2018 to recruit candidates for research collaborations related to drug discovery.
In 2020, we have established a new corporate philosophy that expresses "Our…
Cambridge, UK, 14 December 2022: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, and ThinkCyte K.K, a biotechnology company pioneering novel cell analysis and sorting instruments, today announced a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI). The partnership leverages both companies’ distinctive technologies in high-throughput drug discovery, PhoreMost’s next-generation phenotypic screening platform, SITESEEKER®, and ThinkCyte’s AI-driven cell…